Modular Medical Inc. Common Stock (MODD)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money today and can defend it tomorrow. Modular Medical does neither yet. The company is a 51-employee medical device firm developing the Pivot tubeless insulin pump. In the filed figures, revenue is not available for any period, while net losses persist: fiscal Q1 2027, the quarter ended 2026-06-30, lost $6.5 million; FY2026, the year ended 2026-03-31, lost $28.2 million; FY2025, the year ended 2025-03-31, lost $18.8 million; and FY2024, the year ended 2024-03-31, lost $17.5 million. That is a venture-stage profile, not a proven compounding machine. The balance sheet has little debt, with D/E of 0.03, but trailing free cash flow was -$28.0 million against a $17.4 million market cap, a -160.7% FCF yield. A company burning more than its market value annually must rely on external capital, which risks dilution. Based on the 2026-10-13 close of $2.14, FairStock’s calculations show P/B 1.11, P/E -0.22, ROE -247.94%, ROCE -129.12%, Piotroski 1/9, Altman Z -6.29, and FairStock Score 26/100. Those are distress and weak-fundamentals signals. The Lynch category is none because of losses in each of the last four years. Valuation is not anchored by earnings; the negative P/E merely reflects losses. The 52-week range of $1.72 to $18.78 shows how speculative sentiment has been. The only argument is optionality: if Pivot reaches commercial scale, revenue could appear and losses could narrow. But I see no moat, no revenue, no margin of safety, and no demonstrated ability to fund itself. That is speculation, not value investing.

In plain English: Modular Medical is a small medical device company working on an insulin pump called Pivot. It has no revenue in the periods it has filed and has lost money every year, so the business looks weak and unproven. At $2.14 on 2026-10-13, the price is not supported by profits because there are none; it is a speculative bet on future products.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer